A lipid pharmaceutical preparation and application thereof. The lipid pharmaceutical preparation comprises a local anesthetic and a lipid substance. The mass percentage of the local anesthetic in the lipid pharmaceutical preparation is 2%-50%. The local anesthetic is lidocaine, tetracaine, bupivacaine, articaine, cinchocaine, dibucaine, etidocaine, levobupivacaine, mepivacaine, prilocaine, ropivacaine, trimecaine, benzocaine, or procaine. The mass percentage of the lipid substances in the lipid pharmaceutical preparation is 30%-98%. The sum of the mass percentages of the components in the lipid pharmaceutical preparation is 100%. In general analgesic application, the lipid pharmaceutical preparation can produce continuous and safe analgesic effects for 12, 24, 36, 48, or 72 hours, or even longer.

A lipid pharmaceutical preparation and application thereof. The lipid pharmaceutical preparation comprises a local anesthetic and a lipid substance. The mass percentage of the local anesthetic in the lipid pharmaceutical preparation is 2%-50%. The local anesthetic is lidocaine, tetracaine, bupivacaine, articaine, cinchocaine, dibucaine, etidocaine, levobupivacaine, mepivacaine, prilocaine, ropivacaine, trimecaine, benzocaine, or procaine. The mass percentage of the lipid substances in the lipid pharmaceutical preparation is 30%-98%. The sum of the mass percentages of the components in the lipid pharmaceutical preparation is 100%. In general analgesic application, the lipid pharmaceutical preparation can produce continuous and safe analgesic effects for 12, 24, 36, 48, or 72 hours, or even longer.

A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

The present disclosure generally relates to the field of aerosol generation devices, and more particularly to electronic cigarettes configured to generation of aerosols from aqueous formulations of nicotine or cannabis products. The present disclosure further provides aqueous cannabinoid compositions for use in the aerosol generation devices.

In one aspect, this invention relates to a method for treating pain and subsequent resulting conditions. In yet another aspect, this invention relates to formulating agents to rapidly reverse painful conditions.

In one aspect, this invention relates to a method for treating pain and subsequent resulting conditions. In yet another aspect, this invention relates to formulating agents to rapidly reverse painful conditions.

Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.

Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.

The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.